Lyme disease vaccine demonstrated more than 70% efficacy in preventing disease

Biotech companies, Valneva and Pfizer, announced Monday topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating: